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Abstract
Background: Patellofemoral pain syndrome is a highly prevalent musculoskeletal overuse condition that has a
significant impact on participation in daily and physical activities. A recent systematic review highlighted the lack
of high quality evidence from randomised controlled trials for the conservative management of patellofemoral pain
syndrome. Although foot orthoses are a commonly used intervention for patellofemoral pain syndrome, only two
pilot studies with short term follow up have been conducted into their clinical efficacy.
Methods/design: A randomised single-blinded clinical trial will be conducted to investigate the clinical efficacy
and cost effectiveness of foot orthoses in the management of patellofemoral pain syndrome. One hundred and
seventy-six participants aged 18–40 with anterior or retropatellar knee pain of non-traumatic origin and at least
six weeks duration will be recruited from the greater Brisbane area in Queensland, Australia through print, radio
and television advertising. Suitable participants will be randomly allocated to receive either foot orthoses, flat
insoles, physiotherapy or a combined intervention of foot orthoses and physiotherapy, and will attend six visits
with a physiotherapist over a 6 week period. Outcome will be measured at 6, 12 and 52 weeks using primary
outcome measures of usual and worst pain visual analogue scale, patient perceived treatment effect, perceived
global effect, the Functional Index Questionnaire, and the Anterior Knee Pain Scale. Secondary outcome measures
will include the Lower Extremity Functional Scale, McGill Pain Questionnaire, 36-Item Short-Form Health Survey,
Hospital Anxiety and Depression Scale, Patient-Specific Functional Scale, Physical Activity Level in the Previous
Week, pressure pain threshold and physical measures of step and squat tests. Cost-effectiveness analysis will be
based on treatment effectiveness against resource usage recorded in treatment logs and self-reported diaries.
Discussion: The randomised clinical trial will utilise high-quality methodologies in accordance with CONSORT
guidelines, in order to contribute to the limited knowledge base regarding the clinical efficacy of foot orthoses in
the management of patellofemoral pain syndrome, and provide practitioners with high-quality evidence upon
which to base clinical decisions.
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Background
Patellofemoral pain syndrome (PFP) is a distinct clinical
entity defined as "idiopathic pain arising from the ante-
rior knee/patellofemoral region that is of otherwise
unknown origin" [1]. Falling within the classification of
lower limb musculoskeletal overuse conditions, PFP is
highly prevalent among active individuals. A recent retro-
spective review of running injuries found PFP to be the
most common presentation to a sports medicine clinic in
both females (19.2% of injuries) and males (13.4% of
injuries) [2]. The pain and disability resulting from this
condition not only affects short term participation in
daily and physical activities, but can have a significant
long term impact, with symptoms shown to persist in 1 in
4 sufferers for up to 20 years after initial presentation [3].
As regular physical activity is highly recommended for the
prevention of conditions such as cardiovascular disease
and type II diabetes, PFP may have important implica-
tions for the long term health of affected individuals.
Given the prevalence and impact of this condition and the
subsequent demands placed on health care practitioners,
the lack of high quality research on the conservative man-
agement of PFP is surprising [4,5]. A recent systematic
review by Crossley et al [5] concluded that current man-
agement of PFP is not based on evidence from ran-
domised controlled trials (RCTs), which are widely
deemed to be the gold standard of research design in pro-
viding the best evidence for health care interventions [6].
Foot orthoses are a commonly used and frequently rec-
ommended intervention in the management of PFP [7].
Preliminary evidence of their clinical efficacy is provided
by findings of a pilot study of 20 adolescent females [8].
The addition of soft foot orthoses to an exercise program
resulted in significantly greater improvements in pain
than treatment with flat insoles and exercises over eight
weeks. A more recent study by Wiener-Ogilvie & Jones [9]
however found no difference in outcome between 8 weeks
of treatment with functional foot orthoses, exercises, or
orthoses with exercises. The authors considered the small
sample size (N = 31) to have contributed to the inability
to detect a significant difference between the three groups.
Conversely, a popular physiotherapy program used rou-
tinely in Australia does have high quality RCT evidence to
support its use in PFP. Crossley et al [10] showed this six
week physiotherapy program of quadriceps muscle
retraining, patellofemoral joint mobilisation, patellar tap-
ing and daily home exercises to be significantly superior
to sham ultrasound, non-therapeutic gel application and
placebo taping. The short follow up period used in all
three studies could be considered to be a downfall, partic-
ularly given the condition's demonstrated tendency for
chronicity [3].
In order to provide clinicians with high quality evidence
upon which to base clinical decision making, it is there-
fore timely to conduct a RCT to establish the long term




The primary aim of this study is to determine the clinical
efficacy of foot orthoses in the management of PFP, as
compared to a flat insole, a proven physiotherapy pro-
gram, and a combined intervention of foot orthoses and
physiotherapy. The cost-effectiveness of foot orthoses
compared to the other interventions will also be evalu-
ated.
Study design
The above aims will be investigated through the conduct
of a pragmatic randomised single-blinded clinical trial in
a community setting over a 12 month period. All partici-
pants will provide written informed consent prior to ran-
domisation. The investigator responsible for taking the
outcome measures will be blinded to participants' group
allocation. In order to maintain blinding of this investiga-
tor, randomisation will be effected and controlled by an
independent body, and a research assistant will perform
all communication regarding group allocation. An over-
view of the study protocol is provided in Figure 1.
Ethics
Ethical approval for this study has been granted by the
University of Queensland's Medical Research Ethics Com-
mittee.
Eligibility criteria
Volunteers will be eligible for participation in the study
on the basis of the following criteria: (1) anterior or retro-
patellar knee pain of non-traumatic origin and greater
than six weeks duration that is provoked by at least two of
the following activities: prolonged sitting or kneeling,
squatting, jogging or running, hopping, jumping, or stair
ascending/descending; (2) the presence of pain on palpa-
tion of the patellar facets, on step down from a 25 cm step,
or during a double leg squat; and (3) pain over the previ-
ous week equal to or greater than 30 mm on a 100 mm
visual analogue scale. Due to the nature of the outcome
measures to be used, participants will require an accepta-
ble understanding of written and spoken English. An abil-
ity and willingness to attend all sessions required for
completion of the study and comply with intervention
protocols for the 12 month study period will also be an
essential criterion. Volunteers will be excluded if they
have any of the following: (1) concomitant injury or
pathology of other knee structures (e.g. menisci, collateral
and cruciate ligaments, patellar tendon, iliotibial band,BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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pes anserinus); (2) a history of knee surgery, patellofemo-
ral dislocation or sublaxation, Osgood-Schlatter's disease
or Sinding-Larsen-Johanssen syndrome; (3) a positive
patellar apprehension test; evidence of knee joint effu-
sion; (4) any foot condition that may preclude the use of
foot orthoses; (5) pain in and/or referred from the hip or
lumbar spine; or (6) a known allergy to rigid strapping
tape. Prior treatment with foot orthoses will also preclude
Flow of participants through the randomised clinical trial Figure 1
Flow of participants through the randomised clinical trial.BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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volunteers from participating in order to facilitate blind-
ing as to the differences between the foot orthoses and flat
insoles, as will prior physiotherapy treatment for PFP
within 12 months of entry into the study and current use
of anti-inflammatories or corticosteroids. All participants
will be required to be a minimum of 18 years of age for
consent purposes, and a maximum of 40 years in order to
minimise the likelihood of degenerative joint changes.
Recruitment of study participants
In order to recruit a representative sample of sufficient
size, a multifaceted recruitment strategy that has been suc-
cessful in past clinical trials will be used. This will target
the greater Brisbane, Gold Coast and Toowoomba regions
in Queensland, Australia. Paid advertisements in local
and regional newspapers will be placed at regular intervals
during the recruitment period, along with media releases
to broaden the scope to radio and television media. These
will be reinforced by regular posting of advertisements on
University, gymnasium and community noticeboards
within the catchment area. It is anticipated that a small
number of referrals will also come from physiotherapists
involved in the study, as well as general practitioners
through the provision of information and advertising
packages.
Volunteers who respond to advertisements will be put
through a two-stage screening process to determine their
suitability for inclusion in the study. Firstly, a preliminary
telephone interview will be conducted to screen for major
exclusion criteria. Potential participants will then be
invited to attend an appointment at the University of
Queensland, where they will be provided with further
information about the screening process and study. A
comprehensive musculoskeletal examination will then be
conducted by a qualified physiotherapist to determine the
volunteer's suitability for inclusion based on the eligibil-
ity criteria. At the completion of the examination, eligible
volunteers will be provided with an information sheet
that thoroughly explains the study protocol. They will
then attend a follow-up appointment for completion of
informed consent documentation and baseline outcome
measures. This will be conducted by an assessor who will
remain blind to group allocation and be responsible for
taking outcome measures at designated follow-up times.
At this appointment, the knee rated to be the most severe
by participants with bilateral PFP will be selected as the
knee to be studied.
Randomisation
Once informed consent has been obtained and baseline
outcome measures completed, each participant will be
assigned a participant number and randomly allocated to
one of four intervention groups via concealed allocation.
The Queensland Clinical Trial Centre, an independent off-
site body, will be responsible for generating and main-
taining the randomisation sequence. A research assistant
will perform the communication between the Queens-
land Clinical Trial Centre, participants and project physi-
otherapists to prevent unblinding of the blinded assessor.
Intervention
Interventions will be administered by one of 17 experi-
enced registered physiotherapists (Physiotherapists Board
of Queensland) located throughout the catchment area.
All project physiotherapists will have attended two semi-
nars for explanation and discussion of the intervention
protocols and training in fitting of foot orthoses. A quali-
fied sports physiotherapist who has extensive experience
in the management of PFP with orthotics will conduct
these seminars. A comprehensive manual outlining study
procedures will be provided to all project physiothera-
pists.
Participants will attend six 20–60 minute appointments
over a six week period (i.e. one session per week), with
details of each session recorded by the project physiother-
apist in a treatment log. On completion of the six visits,
participants will continue with a self-management pro-
gram for the remainder of the 12 month study period.
This will incorporate the home exercise program relevant
to their allocated intervention.
The four intervention groups are as follows.
1. Foot orthoses
Participants assigned to this group will be provided with
prefabricated foot orthoses from a commercially available
range (Vasyli International). The orthoses are made of
ethylene-vinyl acetate (EVA) of high (Shore A 75°),
medium (Shore A 60°) or low (Shore A 52°) density, and
have an inbuilt arch support and 6° varus wedge as spec-
ified by the manufacturer. The range includes four types of
orthoses to suit a variety of footwear: full length and three-
quarter length (general use); easy fit (a three-quarter
length with lateral cut-away for narrower footwear e.g.
men's dress shoes); and slim fit (a thin minimally arched
orthosis designed for women's dress/court shoes). In
order to maximise compliance, orthoses will be fitted to
up to four pairs of the participants' shoes, using a stand-
ardised iterative procedure based primarily on perceived
comfort (Figure 2). The first stage will involve selection of
an appropriate device based on the amount of space avail-
able in the shoe (Step 1a) and the length of the partici-
pant's foot (Step 1b). In the first instance, an orthosis
made from the highest density EVA will be used (Step 2).
Following this process, if the orthoses are uncomfortable
when worn in the shoe, the therapist will review the type,
size and density, and then choose an alternative orthosis
that does fit comfortably. If the participant is not satisfiedBMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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with the comfort level of the orthoses, the orthoses will be
customised. This will first involve heat moulding as per
the manufacturer's instructions (Step 3a). This process
involves mildly heating the underside of the orthosis,
placing it in the intended shoe and then having the partic-
ipant stand on it with the foot positioned in its neutral
zone for approximately 60 seconds. If the heat moulding
process alone fails to optimise comfort, the therapist will
sequentially trial the addition of medial wedges of the rear
and forefoot and/or a heel raise to the orthoses (Step 3b).
The medial rearfoot wedges have a manufacturer specified
2° or 4° of inclination, the forefoot wedges 4° or 6° and
the heel raises are 4, 6 or 8 mm thick. The forgoing under-
scores the primary goal of fitting of the orthoses to achieve
a comfortable fit. Once comfort has been achieved, the
effect of the orthoses on performance of a functional task
will be evaluated. This will involve quantification of the
effect of the orthoses on pain-free performance of an activ-
ity identified as pain provocative immediately prior to
orthosis fitting, such as, step ups, step downs or squats. A
substantial increase in the number of pain-free repetitions
that can be performed will be regarded as a success. The
therapist will modify the orthoses in order to improve the
performance of the functional task, but with the funda-
mental aim of ensuring the orthoses are comfortable. This
process of fitting, reviewing and adjusting the orthoses
will continue over the six visits. Participants will also be
given a home exercise program of foot arch-forming exer-
cises and weight-bearing calf stretches to be performed
bilaterally twice daily.
2. Flat inserts
This condition will act as a control for the application of
inserts into the footwear, and will likely account for some
of the potential placebo effects of prescribing an in-shoe
device. The flat inserts will be identical in initial appear-
ance to the foot orthoses described above, made from the
same EVA with identical covering fabric and company
logo. However, this device will be of uniform thickness
along its length (3 mm) and have no inbuilt arch or varus
wedging. The only modification that will be made to this
insert is gentle heat moulding over the six appointments.
Participants will be taught a home exercise program of
minimal balance training, slowly progressing from stand-
ing on one leg while holding a rail for support, to unsup-
ported single leg stance, moving toes up and down, and
with eyes closed. The exercise program will not be rein-
forced as with the other interventions.
3. Physiotherapy
The physiotherapy program will consist of a combined
therapy approach that represents the current Australian
best practice. A recent RCT showed this program to pro-
duce a significantly greater reduction in pain and disabil-
ity over six weeks compared to a placebo intervention
[10]. The major components are outlined in Table 1 and
illustrated in Figures 3 and 4.
4. Foot orthoses and Physiotherapy
Participants assigned to this group will receive both the
foot orthoses and physiotherapy programs as described in
1 and 3 above. Due to the large volume of treatment deliv-
ered, participants in this group may undergo a seventh
Sequential procedure for fitting of foot orthoses Figure 2
Sequential procedure for fitting of foot orthoses.BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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visit with the physiotherapist to ensure adequate fit and
comfort of the orthoses and understanding and progres-
sion of the physiotherapy exercise program.
All participants will receive an educational package at the
commencement of the study, providing general informa-
tion on PFP and advice on activity. In general terms, the
advice on activity will entail an encouragement to partici-
pants to continue to exercise and participate in activities
that do not provoke their knee pain, and to avoid aggra-
vating activities particularly if the provoked pain persists
longer than several minutes after cessation of the activity.
Outcome measures
The blinded assessor will repeat the outcome measures
following completion of the 6 visits with the physiothera-
pist at 6 weeks, and then at 12 and 52 weeks to assess the
long term outcome of the intervention.
Outcome will be assessed at each time point using meas-
ures that have been previously demonstrated as being
acceptably reliable and valid indictors of change [11-16]
and used in previous high-quality RCTs of PFP [10,17,18].
The primary outcome measures will be as follows.
1. Usual and worst pain Visual Analogue Scale
A 100 mm horizontal line with the descriptors 'no pain' at
the 0 mm mark and 'worst pain imaginable' anchoring the
100 mm end will be used as a visual analogue scale. Par-
ticipants will be required to place a vertical mark that rep-
resents their pain level on the horizontal line. They will do
this twice, once to indicate their usual level of pain in the
preceding week and the other to represent their worst pain
Table 1: Physiotherapy program (adapted from Crossley et al, 2002).
Intervention Dose
Patellar mobilisation:
I. Passive patellar medial glide and tilt combined with transverse friction massage of the lateral retinaculum 4 × 30 seconds
Stretches:
I. Hamstring stretches 3 × 20 seconds; bilateral
II. 'Figure 4' anterior hip stretch (Figure 3) 3 × 20 seconds; bilateral
Patellar taping:
I. Taping of the patella: Daily application for 6 weeks
1. Medial tilt and posterior tilt
2. Medial glide and posterior tilt
3. Fat pad unloading
4. Medial rotation
Exercises:
I. Hip external rotation retraining (Figure 4) 3 × 20 seconds; bilateral
II. Vasti retraining (with EMG biofeedback):
i. Isometric VMO contraction in sitting 3 × 10 repetitions (affected);
1 × 10 repetitions (unaffected)
ii. Inner range knee flexion in standing 3 × 10 repetitions
iii. Step downs (when able to perform 5 pain-free repetitions):
a) Slow eccentric lowering on affected leg from 10 cm step 3 × 10 repetitions
b) Increased step height (20 cm step) 3 × 10 repetitions
c) Alternating speed (down slow, up fast; down fast, up slow) 3 × 10 repetitions
Home exercise program:
I. Self-mobilisation of the affected patella As above; twice daily
II. Patellar taping (as above)
III. Stretches (as above)
IV. Exercises (as above)
'Figure 4' anterior hip stretch in prone Figure 3
'Figure 4' anterior hip stretch in prone.BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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experienced over the same time period. This will give two
perceived pain severity ratings in millimetres [19]. The
pain VAS has well-established reliability and validity in
individuals with AKP [11,14,15,19].
2. Anterior Knee Pain Scale
This scale consists of 13 items with discrete categories
related to limp, weight bearing, walking, stairs, squatting,
running, jumping, prolonged sitting with flexed knees,
pain, swelling, painful patellar movements, thigh muscle
atrophy, and flexion deficiency. One response to each
item that best describes the participant's knee pain is
selected and scored on a weighted basis, with the highest
representing normal and asymptomatic [20]. The 13 indi-
vidual items are then summed to provide a final score
where 0 represents maximal disability and 100 represents
no disability. This scale has been shown to have high test-
retest reliability [15,16], moderate responsiveness to clin-
ical change [16], and a demonstrated ability to discrimi-
nate between individuals with and without AKP [20].
3. Functional Index Questionnaire
The Functional Index Questionnaire comprises eight
questions pertaining to whether activities that are com-
monly problematic in PFP can be performed with or with-
out difficulty [14,19]. The activities, including prolonged
sitting, squatting and stair climbing, are each rated on a
three point scale, where 0 = unable to do, 1 = can do with
problem, and 2 = no problem. The sum of the scores for
each of the eight activities provides an overall score, with
0 indicating maximal disability and 16 representing no
disability. Studies have shown the FIQ to have fair to sub-
stantial test-retest reliability [11,14,15,19], and to be a
valid measure for detection of clinical change [14].
4. Patient Perceived Treatment Effect Score and Perceived Global 
Effect Visual Analogue Scale
Participants' perceived level of recovery will be rated on
two scales at the 6, 12 and 52 week follow-up visits. Per-
ceived Treatment Effect will be measured using a 5 point
Likert scale with the following categories: (1) marked
worsening, (2) moderate worsening, (3) same, (4) mod-
erate improvement, and (5) marked improvement. For
the purpose of analysis, this scale will then be dichot-
omised according to success, where 'success' is defined as
marked or moderate improvement on this scale [10]. We
will also conduct a sensitivity analysis on this dichotomi-
sation. Perceived Global Effect Visual Analogue Scale will
be piloted. Participants will rate their recovery by placing
a vertical mark on a 200 mm VAS with 'same' in the mid-
dle to represent no change (0 mm), 'much worse' at the far
left end (-100 mm) and 'completely better' as the right
hand anchor (+100 mm). A positive score will represent
improvement, while a negative score will indicate worsen-
ing of the condition.
Hip external rotation retraining Figure 4
Hip external rotation retraining.BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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Secondary outcome measures that will be taken include
the following:
1. Lower Extremity Functional Scale
The Lower Extremity Functional Scale is used to evaluate
any difficulty experienced during daily activities as a result
of the specific lower limb condition, such as PFP, and has
been shown to be reliable, valid and sensitive to change in
AKP participants [16] and those with general lower limb
conditions [12]. Twenty items are rated individually on a
5 point scale indicating the degree of difficulty associated
with performing that activity on the current day, ranging
from 0 (extreme difficulty or unable to perform the activ-
ity) to 4 (no difficulty). Scores from each activity are
summed to give an overall indication of functional diffi-
culty, where 0 indicates maximal difficulty and 80 indi-
cates no difficulty.
2. Patient-Specific Functional Scale
The Patient Specific Functional Scale assesses individual
disabilities in a short, efficient format, and was designed
to complement generic or condition-specific measures
[13]. It has been shown to have excellent test-retest relia-
bility and sensitivity, and good validity in individuals
with knee dysfunction [13]. Participants are asked to
nominate up to 5 functional activities that they are expe-
riencing difficulty with. The current level of difficulty asso-
ciated with each activity due to the specified condition is
then rated on an 11-point scale, where 0 is "unable to per-
form the activity" and 10 is "able to perform activity at
same level as before injury or problem", and the average
score across all activities is calculated.
3. McGill Pain Questionnaire
The most commonly used multidimensional pain meas-
ure, the McGill Pain Questionnaire provides a description
of the participant's pain experience, and has been utilised
as a primary outcome measure in previous knee pain stud-
ies [21,22]. The first component involves descriptors of
pain categorised as sensory, affective, evaluative and mis-
cellaneous. Twenty groups of words are presented, with
the participant required to select one word from each
group that best describes their pain. The word chosen is
scored by its rank order within the group, with the first
word scoring 1, the second word scoring 2, and so forth.
If no words are applicable a score of zero is recorded for
that group. The Pain Rating Index is the sum of the scores
across the 20 groups (range 0–78). The Number of Words
Chosen is the number of groups for which a word was
selected (out of 20). The second component is the Present
Pain Index, a six point scale of severity ranging from no
pain (0) to excruciating (5). For the final component, the
participant selects one of three groups of words that best
describes the pattern of their knee pain, or how pain
changes with time, and leaves the question blank if there
is no pain.
4. Medical Outcomes Study 36-Item Short-Form Health Survey
This questionnaire is a widely-used generic measure of
health-related quality of life [23], and has been previously
used in PFP populations [10]. Thirty-six items are used to
calculate eight multi-item scores: physical functioning,
role limitations due to physical health problems, bodily
pain, general health, vitality (energy/fatigue), social func-
tioning, role limitations due to emotional problems, and
mental health.
5. Hospital Anxiety and Depression Scale
This 14-item scale will be used to investigate whether
there is an association between PFP and emotional state,
and has been found to be a reliable instrument for detec-
tion of anxiety and depression in an outpatient setting
and a valid indicator of severity [24], and has been used in
a previous study of physiotherapy in PFP [17]. Partici-
pants are required to select the best of 4 responses to ques-
tions pertaining to either anxiety or depression (7
questions each), which are scored from 0 to 3. The scores
for the anxiety and depression questions are summed sep-
arately to give total scores for each component, where 0–7
represents no anxiety or depression, 8–10 is borderline,
and 11–21 indicates the presence of an anxious or depres-
sive state.
6. Physical Activity Level in the Previous Week
Participants' physical activity levels will be quantified
using a physical activity questionnaire by which occupa-
tional, household and leisure activities of varying intensi-
ties can be accurately and reliably measured [25]. This
questionnaire involves calculation of the time spent in
each of these activity types at moderate, hard and very
hard intensities over the preceding 7 days. The total time
in hours for each intensity of activity is then multiplied by
the metabolic equivalents of the activities (METs, kcal/kg/
hour), and summed to give an overall caloric output for
the week, and divided by seven to give an average daily
output. This can then be standardised to body weight to
provide an index that can be compared between and
within individuals across time [25]. This questionnaire
has been shown to have moderate to high reliability on
test-retest, especially with moderate and vigorous intensi-
ties of activity [25], and has been used previously in a PFP
population [10].
7. Step up, step down and squat tests
Three activities that typically provoke PFP will be used as
a physical measure of function [10]. Step up and step
down tests will be performed on a 25 cm step in a step-
ping order that continually loads the study knee, while
squats will be of full excursion to the point where the fin-BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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gers touch the floor. A metronome set at 96 beats per
minute will be used to standardise the rate of testing. The
repetition number on which the first onset of pain occurs,
or the first increase in pain where a constant background
ache is present, will be recorded, up to a maximum of 25
repetitions.
8. Pressure Pain Threshold (PPT)
Pressure algometry, which has demonstrated reliability
[26], will be used to measure PPT at four sites at the knee:
(1) the proximal third of the medial border of the tibia;
(2) the midpoint of the patella; (3) the distal portion of
the rectus femoris muscle, 5 cm superior to the proximal
border of the patella; (4) the most palpably tender point
around the knee. A digital pressure algometer (Somedic
AB, Farsta, Sweden) will measure the pressure applied at a
rate of 40 kPa/s to the test site by a rubber-tipped probe
(area 1 cm2) positioned perpendicular to the skin. The
participant will activate a button at the precise moment
that the pressure sensation changes to one of pressure and
pain, which will signal cessation of pressure application
and freeze the pressure reading onscreen for manual
recording. Three measures will be taken at each site and
the average calculated to represent the final value.
A further questionnaire regarding any adverse reactions to
the intervention and whether any other treatment was
sought will be completed at 12 months.
All participants will be required to maintain a daily diary
over the 12 month period, recording activity levels, prob-
lems with the intervention, analgesia requirements and
compliance with the home exercise program. Visual ana-
logue scales for usual and worst pain over a week period
will also be recorded.
Sample size considerations
Sample size calculations for this study are based on the
100 mm visual analogue scale for usual pain over the past
week. The mean difference between baseline and final
score for each group will be compared to measure the
effectiveness of each intervention. In order to detect a
minimal clinically important difference of 15 mm
[15,27], assuming a standard deviation of 20 mm [10], a
power of 0.80 and alpha level of 0.01, a sample size of 40
participants per group will be required. To account for
dropouts, particularly considering the long duration of
the study [28], a group size of 44 will be recruited, with a
total sample size of 176.
Planned statistical analysis
Statistical analysis will be conducted on a blinded, inten-
tion to treat basis, with all participants who were initially
randomised into the study included where data is availa-
ble for each measurement time. SPSS software (Version
15.0) will be used for statistical procedures. The four
groups will be examined for baseline comparability with
respect to demographic data such as age, gender, body
mass index and duration of knee pain, as well as baseline
values of outcome measures. Continuous outcome meas-
ures taken at 6, 12 and 52 weeks will be analysed using
univariate analysis of variance, where the baseline value of
the outcome measure will be used as a covariate and
group allocation as a fixed factor. Continuous data will
also be expressed as area under the curve in order to com-
pare the overall effectiveness of each intervention over the
entire 12 month period. Participant demographics will
also be included in the models as covariates to assess their
impact on outcome. The dichotomous measure of success
will be analysed using relative risk, risk reduction and
numbers needed to treat in order to facilitate clinical inter-
pretation of findings and future guidelines. Cost effective-
ness analysis will evaluate the effectiveness of the
intervention measured using Perceived Treatment Effect
against resource usage (e.g. physiotherapist fees, equip-
ment, medications, etc.), through calculation of the mar-
ginal cost effectiveness of treatment in terms of dollars per
1-point improvement in outcome. To accommodate for
the possibility of inflated Type I error rate resulting from
multiple comparisons, significance will be set at 0.01 (i.e.,
99% confidence intervals).
Discussion
In order to determine the clinical efficacy and cost-effec-
tiveness of foot orthoses in the management of PFP, a
pragmatic randomised clinical trial is to be conducted.
Based on the Delphi List of criteria for quality assessment
of RCTs [29], particular methodological factors have been
incorporated into the study design to minimise bias and
optimise the rigor of the RCT. Firstly, participants will be
randomly allocated to intervention groups via concealed
allocation. Poor allocation concealment has been shown
to be associated with bias in RCTs [30]. Secondly, the
investigator responsible for assessment of outcome at
each time point will remain blind to participants' group
allocation. Although it could be argued that the use of
self-reported primary outcome measures may itself reduce
bias associated with an unblinded assessor, blinding of
outcome assessors is still an important component due to
the potential for transfer of attitudes regarding an inter-
vention from the assessor to the participant [31]. In this
study, blinding of participants and the physiotherapists
administering treatment is not possible due to the nature
of the interventions used. However, as it has been recom-
mended that greater credence should be placed in results
where at least the investigators have been blinded to
group allocation [31], the single-blind nature of this study
is not deemed to be a methodological flaw. Thirdly, the
investigators responsible for statistical analysis will be
blind to the treatment group allocation, thereby minimis-BMC Musculoskeletal Disorders 2008, 9:27 http://www.biomedcentral.com/1471-2474/9/27
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ing the likelihood of bias associated with their anticipated
outcomes. Fourthly, the data analysis will proceed on an
intention-to-treat basis, which amongst other things,
maintains randomisation, conservatively manages infla-
tion of type I error rate and imitates real life in which it is
somewhat likely that not all patients will receive the ideal
or intended treatment that has been prescribed.
As recommended by the CONSORT group [6], the RCT
design has endeavoured to utilise outcome measures that
have established reliability and validity and, where possi-
ble, have been used previously in PFP participants. This
not only enhances the quality of the measurement and
outcomes, but also facilitates direct comparisons with
other studies that have investigated interventions for PFP
and possible meta-analyses in the future. Furthermore,
the selection of clinically applicable primary outcome
measures that are easily administered in a clinical setting
improves the clinical relevance of study findings.
The foot orthoses chosen for use in the RCT are a range of
prefabricated devices that are widely used in Australian
clinical practice. These orthoses were chosen over a cus-
tom moulded device on the basis of clinical time
restraints, the higher direct cost of custom moulded
orthoses, and findings from a recent meta-analysis of sim-
ilar benefits for both types of devices in the management
of lower limb overuse conditions [32]. In fitting the
orthoses, we will adopt an approach based on a key syn-
optic paper by Nigg et al [33]. On the basis of evidence
that does not support the traditional concept that inserts
and orthoses are used to align the skeleton, they proposed
a new concept for the function and fitting of shoes and
shoe inserts. This new concept includes the following: (a)
the skeleton has a preferred path for a given movement
task; (b) if an intervention (shoe and/or insert) supports
this preferred path, muscle activity can be reduced; (c) an
optimal shoe and/or insert feels comfortable because it
reduces muscle activity and the resulting fatigue; and (d)
performance should increase with an optimal shoe and/or
insert since muscle activity is minimised and thus energy
expenditure is reduced. Therefore, the participants' per-
ception of comfort will be used as the key guide for the
selection and fitting of the appropriate orthoses. Although
the orthoses are prefabricated, they do allow for a degree
of modification in order to achieve best comfort fit. Once
comfort has been achieved, using the steps outlined in
Figure 2, if required, the device will be further modified to
improve pain-free performance of a pain provocative
functional task whilst still being comfortable. This is
based on the proposition that the orthoses should mini-
mise the patient's pain during function [34].
A particular feature of this study is the inclusion of flat
inserts as an experimental control. This assumes that the
shaped contoured form of the rear and mid-section of a
moulded orthosis is its active constituent in controlling
foot motion, especially excessive pronation. It is the con-
trol of motion that has traditionally been viewed by prac-
titioners, and indeed intuitively by patients, as a major
function of orthoses [35-37]. To the extent that the con-
toured form of an orthosis is conceptualised to be its
active constituent, the control flat insert may then be
regarded as a placebo. However, it has not been conclu-
sively proven that orthoses do control motion, with some
studies indicating no systematic effect on motion [38,39]
and others to the contrary [40-42]. An alternative view is
that foot orthoses simply serve as space fillers, with their
shaped form facilitating full plantar contact [43], which is
regarded by some to be clinically beneficial [44,45]. We
contend that the inclusion of a flat insert as an experimen-
tal control condition is especially important due to the
inconsistencies in findings and viewpoints surrounding
foot orthoses.
In summary, the RCT to be conducted will utilise high-
quality methodologies in accordance with CONSORT
guidelines. It is anticipated that findings from this study
will contribute to the limited knowledge base regarding
the clinical efficacy of foot orthoses in the management of
PFP, and provide clinicians with high-quality evidence
upon which to base clinical decision making.
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